Annexin Pharmaceuticals AB
7.82
SEK
-0.54
(-6.46%)
ISIN
SE0025159387
Return %
Stock
S&P 500
1Y
-69.23
14.20
3Y
-77.45
81.12
5Y
-88.71
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Nils Anders Haegerstrand
- Full Time Employees
- 4
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Kammakargatan 48 Stockholm AB Sweden 111 60
- IPO Date
- Apr 19, 2017
- Website
- annexinpharma.com
- Similar Companies
- Business
- Annexin Pharmaceuticals AB (publ) is a Sweden-based clinical-stage biotechnology company focused on developing innovative therapies leveraging Annexin A5 biology for diseases involving vascular damage, inflammation, and immune dysregulation; it advances its lead investigational drug candidate ANXV, a recombinant human protein Annexin A5 produced via patented methods in Escherichia coli, which binds to phosphatidylserine on damaged cell membranes to provide cell protection, immune modulation, anti-inflammatory effects, anti-thrombotic properties, and tissue repair. ANXV targets multiple indications including retinal vein occlusion (RVO), a sight-threatening condition affecting over 16 million people globally, where it is evaluated in an ongoing Phase 2a proof-of-concept study demonstrating promising signals of clinical effect such as durable visual acuity improvements and reduced need for anti-VEGF injections in a majority of treated patients; oncology applications encompassing ANXV as monotherapy, combination immunotherapy, or chemotherapy conjugate carrier showing preclinical efficacy in triple-negative breast cancer; and exploratory areas like sickle cell disease, cardiovascular disorders, inflammatory joint and bowel diseases, sepsis, and traumatic brain injury. The company maintains a robust patent portfolio covering ANXV production processes, therapeutic uses in RVO and cancer via in-licenses such as from Stanford University, and label expansion opportunities. Founded in 2014 and headquartered in Stockholm, Sweden, Annexin Pharmaceuticals operates primarily in Europe and the United States through clinical trial sites and contract partners, with no subsidiaries or parent entities, and employs a small team of four while listed on Nasdaq First North Growth Market (ticker: ANNX.ST). Recent developments include the successful completion of a rights issue in March 2025 raising approximately SEK 50 million before costs, fully subscribed with 100% uptake including commitments from shareholders and a top guarantee consortium to fund Phase 2a expansion into diabetic retinopathy and Phase 2b in RVO; database lock and positive top-line results from the RVO Phase 2a study in February 2025 confirming clinically relevant efficacy signals alongside a favorable safety profile with no limiting adverse events across 11 patients; establishment of a Medical Advisory Board in ophthalmology; continued oncology progress with preclinical ANXV-chemotherapy conjugates; and heightened partnering interest following presentations at conferences like JP Morgan Healthcare, positioning the company for licensing deals in ophthalmology and oncology ahead of further clinical milestones.